Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biosyent Inc (RX.VN)

Biosyent Inc (RX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 99,262
  • Shares Outstanding, K 11,610
  • Annual Sales, $ 31,590 K
  • Annual Income, $ 6,460 K
  • 60-Month Beta 0.40
  • Price/Sales 3.26
  • Price/Cash Flow 20.59
  • Price/Book 2.86
Trade RX.VN with:
  • Price/Earnings ttm 16.10
  • Earnings Per Share ttm 0.53
  • Most Recent Earnings $0.12 on N/A
  • Latest Earnings Date 05/24/24
  • Annual Dividend & Yield 0.16 (2.11%)
  • Most Recent Dividend 0.045 on 02/28/24
  • Sectors:

    TSX Drug Specialty & Generic

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.08
  • Number of Estimates 1
  • High Estimate 0.08
  • Low Estimate 0.08
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.450 unch
on 04/18/24
8.750 -3.43%
on 04/08/24
-0.140 (-1.63%)
since 03/18/24
3-Month
8.400 +0.60%
on 01/19/24
8.820 -4.20%
on 03/06/24
unch (unch)
since 01/18/24
52-Week
7.030 +20.20%
on 07/06/23
9.260 -8.75%
on 12/29/23
+0.830 (+10.89%)
since 04/18/23

Most Recent Stories

More News
BioSyent Releases Financial Results for Q1 2022

MISSISSAUGA, Ontario, May 18, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three...

RX.VN : 8.450 (-1.17%)
BioSyent Schedules Q1 2022 Earnings Release for May 18, 2022

MISSISSAUGA, Ontario, May 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results...

RX.VN : 8.450 (-1.17%)
BioSyent to Present at 2022 Bloom Burton & Co. Healthcare Investor Conference

MISSISSAUGA, Ontario, April 26, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at...

RX.VN : 8.450 (-1.17%)
BioSyent Announces Grant of Restricted Share Units

MISSISSAUGA, Ontario, March 31, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of...

RX.VN : 8.450 (-1.17%)
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2021

MISSISSAUGA, Ontario, March 09, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three...

RX.VN : 8.450 (-1.17%)
BioSyent Schedules Q4 and Full Year 2021 Earnings Release for March 9, 2022

MISSISSAUGA, Ontario, March 03, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial...

RX.VN : 8.450 (-1.17%)
BioSyent Adopts Advance Notice By-law

MISSISSAUGA, Ontario, Feb. 11, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that its Board of Directors...

RX.VN : 8.450 (-1.17%)
BioSyent Announces Renewal of Normal Course Issuer Bid

MISSISSAUGA, Ontario, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX...

RX.VN : 8.450 (-1.17%)
BioSyent Releases Q3 and YTD 2021 Financial Results

MISSISSAUGA, Ontario, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three...

RX.VN : 8.450 (-1.17%)
BioSyent Releases Q2 and H1 2021 Financial Results

MISSISSAUGA, Ontario, Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021. Key highlights...

RX.VN : 8.450 (-1.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 8.583
2nd Resistance Point 8.557
1st Resistance Point 8.503
Last Price 8.450
1st Support Level 8.423
2nd Support Level 8.397
3rd Support Level 8.343

See More

52-Week High 9.260
Last Price 8.450
Fibonacci 61.8% 8.408
Fibonacci 50% 8.145
Fibonacci 38.2% 7.882
52-Week Low 7.030

See More

Business Summary

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar